A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Incyte Corporation
Stanford University
Incyte Corporation
Eilean Therapeutics
Eilean Therapeutics
University of Alabama at Birmingham
Incyte Corporation
Incyte Corporation
Incyte Corporation
Prelude Therapeutics
iOnctura
City of Hope Medical Center
Incyte Corporation
Washington University School of Medicine
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
University of Chicago
City of Hope Medical Center
Mayo Clinic
Hangzhou GluBio Pharmaceutical Co., Ltd.
AbbVie
American Regent, Inc.
University of Virginia